Capitol Hill staffers are signaling that Congress will not interfere with FDA’s plan to further regulate clinical laboratories via its proposed lab-developed test guidance in the short-term, despite some heavy opposition lobbying from the laboratory industry and various alternative regulatory schemes for diagnostics being floated to lawmakers.
Even before FDA proposed its LDT framework